Literature DB >> 11399668

Effects of pH on the inhibition of fatty acid amidohydrolase by ibuprofen.

S Holt1, J Nilsson, R Omeir, G Tiger, C J Fowler.   

Abstract

The pharmacological properties of fatty acid amidohydrolase (FAAH) at different assay pH values were investigated using [(3)H]-anandamide ([(3)H]-AEA) as substrate in rat brain homogenates and in COS-1 [corrected] cells transfected with wild type and mutant FAAH. Rat brain hydrolysis of [(3)H]-AEA showed pH dependency with an optimum around pH 8-9. Between pH 6.3 and 8.2, the difference in activity was due to differences in the V(max), rather than the K(M) values. For inhibition of rat brain [(3)H]-AEA metabolism by a series of known FAAH inhibitors, the potencies of the enantiomers of ibuprofen and phenylmethylsulphonyl fluoride (PMSF) were higher at pH 5.28 than at pH 8.37, whereas the reverse was true for oleyl trifluoromethylketone (OTMK) and arachidonoylserotonin. At both pH values, (-)ibuprofen was a mixed-type inhibitor of FAAH. The K(i)((slope)) and K(i)((intercept)) values for (-)ibuprofen at pH 5.28 were 11 and 143 microM, respectively. At pH 8.37, the corresponding values were 185 and 3950 microM, respectively. The pH dependency for the inhibition by OTMK and (-)ibuprofen was also seen in COS-1 [corrected] cells transiently transfected with either wild type, S152A or C249A FAAH. No differences in potencies between the wild type and mutant enzymes were seen. It is concluded that the pharmacological properties of FAAH are highly pH-dependent. The higher potency of ibuprofen at lower pH values raises the possibility that in certain types of inflamed tissue, the concentration of this compound following oral administration may be sufficient to inhibit FAAH.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11399668      PMCID: PMC1572815          DOI: 10.1038/sj.bjp.0704113

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  39 in total

1.  Pharmacokinetics of ibuprofen in man: a single-dose comparison of two over-the-counter, 200 mg preparations.

Authors:  P Karttunen; V Saano; P Paronen; P Peura; M Vidgren
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1990-06

2.  Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides.

Authors:  B F Cravatt; D K Giang; S P Mayfield; D L Boger; R A Lerner; N B Gilula
Journal:  Nature       Date:  1996-11-07       Impact factor: 49.962

3.  Characterization of the kinetics and distribution of N-arachidonylethanolamine (anandamide) hydrolysis by rat brain.

Authors:  C J Hillard; D M Wilkison; W S Edgemond; W B Campbell
Journal:  Biochim Biophys Acta       Date:  1995-08-03

4.  Partial purification and characterization of the porcine brain enzyme hydrolyzing and synthesizing anandamide.

Authors:  N Ueda; Y Kurahashi; S Yamamoto; T Tokunaga
Journal:  J Biol Chem       Date:  1995-10-06       Impact factor: 5.157

5.  Anandamide amidohydrolase activity in rat brain microsomes. Identification and partial characterization.

Authors:  F Desarnaud; H Cadas; D Piomelli
Journal:  J Biol Chem       Date:  1995-03-17       Impact factor: 5.157

6.  A proposed autacoid mechanism controlling mastocyte behaviour.

Authors:  L Aloe; A Leon; R Levi-Montalcini
Journal:  Agents Actions       Date:  1993

7.  Two novel classes of neuroactive fatty acid amides are substrates for mouse neuroblastoma 'anandamide amidohydrolase'.

Authors:  S Maurelli; T Bisogno; L De Petrocellis; A Di Luccia; G Marino; V Di Marzo
Journal:  FEBS Lett       Date:  1995-12-11       Impact factor: 4.124

8.  Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist.

Authors:  D G Deutsch; S A Chin
Journal:  Biochem Pharmacol       Date:  1993-09-01       Impact factor: 5.858

9.  N-(2-hydroxyethyl)hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by down-modulating mast cell activation.

Authors:  S Mazzari; R Canella; L Petrelli; G Marcolongo; A Leon
Journal:  Eur J Pharmacol       Date:  1996-04-11       Impact factor: 4.432

10.  Arachidonoyl ethanolamide-[1,2-14C] as a substrate for anandamide amidase.

Authors:  R L Omeir; S Chin; Y Hong; D G Ahern; D G Deutsch
Journal:  Life Sci       Date:  1995       Impact factor: 5.037

View more
  13 in total

Review 1.  The case for the development of novel analgesic agents targeting both fatty acid amide hydrolase and either cyclooxygenase or TRPV1.

Authors:  C J Fowler; P S Naidu; A Lichtman; V Onnis
Journal:  Br J Pharmacol       Date:  2009-02       Impact factor: 8.739

2.  Analgesic actions of N-arachidonoyl-serotonin, a fatty acid amide hydrolase inhibitor with antagonistic activity at vanilloid TRPV1 receptors.

Authors:  S Maione; L De Petrocellis; V de Novellis; A Schiano Moriello; S Petrosino; E Palazzo; F Sca Rossi; D F Woodward; V Di Marzo
Journal:  Br J Pharmacol       Date:  2007-02-05       Impact factor: 8.739

3.  Anandamide metabolism by fatty acid amide hydrolase in intact C6 glioma cells. Increased sensitivity to inhibition by ibuprofen and flurbiprofen upon reduction of extra- but not intracellular pH.

Authors:  Sandra Holt; Christopher J Fowler
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-02-20       Impact factor: 3.000

Review 4.  Mechanisms of non-opioid analgesics beyond cyclooxygenase enzyme inhibition.

Authors:  May Hamza; Raymond A Dionne
Journal:  Curr Mol Pharmacol       Date:  2009-01       Impact factor: 3.339

5.  A binding site for nonsteroidal anti-inflammatory drugs in fatty acid amide hydrolase.

Authors:  Laura Bertolacci; Elisa Romeo; Marina Veronesi; Paola Magotti; Clara Albani; Mauro Dionisi; Chiara Lambruschini; Rita Scarpelli; Andrea Cavalli; Marco De Vivo; Daniele Piomelli; Gianpiero Garau
Journal:  J Am Chem Soc       Date:  2012-12-21       Impact factor: 15.419

6.  Interaction of ligands for the peroxisome proliferator-activated receptor gamma with the endocannabinoid system.

Authors:  A Lenman; C J Fowler
Journal:  Br J Pharmacol       Date:  2007-06-25       Impact factor: 8.739

Review 7.  The contribution of cyclooxygenase-2 to endocannabinoid metabolism and action.

Authors:  C J Fowler
Journal:  Br J Pharmacol       Date:  2007-07-09       Impact factor: 8.739

8.  Synergy between enzyme inhibitors of fatty acid amide hydrolase and cyclooxygenase in visceral nociception.

Authors:  Pattipati S Naidu; Lamont Booker; Benjamin F Cravatt; Aron H Lichtman
Journal:  J Pharmacol Exp Ther       Date:  2008-12-31       Impact factor: 4.030

9.  Fatty acid amide hydrolase inhibition normalises bladder function and reduces pain through normalising the anandamide/palmitoylethanolamine ratio in the inflamed bladder of rats.

Authors:  Ana Charrua; Rita Matos; Raquel Oliveira; Tim Marczylo; Istvan Nagy; Francisco Cruz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-09-15       Impact factor: 3.000

Review 10.  Endocannabinoid metabolism and uptake: novel targets for neuropathic and inflammatory pain.

Authors:  M D Jhaveri; D Richardson; V Chapman
Journal:  Br J Pharmacol       Date:  2007-08-20       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.